The Mechanism of Action and Toxicity Profile of Duvelisib (IPI-145)

Clinical Pearls

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses the mechanism of action and toxicity profile of duvelisib (IPI-145). Duvelisib is being studied for the treatment of hematologic malignancies.

• Duvelisib inhibits both delta and gamma isoform.
• The hope is that the molecule targets both the tumor cell as well as the microenvironment.
• The toxicity profile of duvelisib is still being studied.
• To date, the molecule appears to have a similar toxicity profile of other PI3K inhibitors.